Pregabalin Capsule
Product Images NDC 71205-304

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71205-304). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-304-60 (Pregabalin Caps 75mg 90s Count)

Label for Pregabalin 75 mg capsules by Proficient Rx LP. The label shows a 60-count package of oral capsules with each capsule containing 75 mg of pregabalin. Capsules are described as size 4 hard gelatin with an orange opaque cap and white opaque body imprinted with "SG" on cap and "352" on body in black ink. The label includes the NDC 71205-304-60 and manufacturer SciGen Pharmaceuticals, Inc. Store at 25°C (77°F).*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A cumulative distribution plot showing percent of patients improved on the y-axis versus percent improvement in pain from baseline on the x-axis. The plot compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. Lines indicate greater patient improvement with increasing Pregabalin doses.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved against percent improvement in pain from baseline. It shows two lines representing Pregabalin 100 mg three times a day and placebo, indicating the relative effectiveness over a range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares the effects of Pregabalin dosed at 75 mg, 150 mg, and 300 mg two times a day to placebo, showing different response rates across the pain improvement spectrum.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting percent improvement in patients' pain from baseline on the x-axis and percent of patients improved on the y-axis. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing the effectiveness of each treatment over the range of pain improvement percentages.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph showing percent improvement in pain from baseline on the horizontal axis and percent of patients improved on the vertical axis. The chart compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating their relative pain improvement outcomes.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart presenting responder rates (%) from two clinical studies, Study E1 and Study E3. The chart compares placebo and various dosages of pregabalin administered BID or TID, showing increasing responder rates with higher dosages. Statistically significant results versus placebo are indicated for multiple doses.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A dose-response line graph showing seizure reduction as median percentage change from baseline versus dose in mg/day. The graph compares results from four studies (E1 BD, E2 TID, E3 BD, E3 TID) with significant p-values noted. Placebo dose is indicated at zero.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing percent improvement in pain from baseline on the x-axis versus percent of patients improved on the y-axis. The graph compares four groups: Pregabalin 800 mg daily dose, 450 mg daily dose, 300 mg daily dose, and a placebo, each represented with different line styles. Vertical lines mark specific points around 30 and 50 percent pain improvement.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A line graph comparing Pregabalin and placebo over 180 days. The y-axis shows estimated percentage of subjects without LTR (loss of therapeutic response) from 0% to 100%, starting near 100%. The x-axis shows time in days from 0 to 180. Pregabalin's solid line shows a slower decline in subjects without LTR over time compared to the placebo's dashed line, which declines more sharply.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line chart comparing the percent of subjects improved over time from baseline to week 12 between Pregabalin and Placebo groups. The x-axis represents percent improved from baseline to week 12 BOCF, ranging from 0 to 100, and the y-axis shows the percent of subjects improved, ranging from 0 to 100. The solid line represents Pregabalin, and the dashed line represents Placebo, with Pregabalin consistently showing higher improvement percentages.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line chart comparing the percent of subjects improved over a range of percent improvement from baseline to week 16 BOCF. Two lines represent Pregabalin and Placebo groups, showing higher improvement percentages for Pregabalin across the range.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A pharmacokinetic formula calculation depicting creatinine clearance (CLcr). The equation accounts for age in years, weight in kilograms, serum creatinine in mg/dL, and adjusts the result by multiplying by 0.85 for female patients. This formula is commonly used in drug dosing considerations.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of the active ingredient pregabalin, depicted as its molecular structural formula showing atoms and bonds characteristic of this compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.